As the COVID-19 pandemic spreads throughout the United States and Americans anxiously await the arrival of a vaccine, biotech companies are grappling with the uncertainty of patent protection for COVID related biomedical advances and, as a result, are turning to trade secret protection instead. For policy-makers looking to incentivize the search for the magic bullet of an effective vaccine, this raises tough questions: What is the best policy or mix of policies to incentivize industry and stimulate a rapid, effective vaccine? And should that policy tilt towards sharing information or towards protecting monetary incentives? This article addresses the limitations on patent eligibility, the role of trade secret protection, and the current federal policy landscape on biological innovation incentives during the pandemic.
Continue Reading Trade Secret Protection & the COVID-19 Cure: Observations on Federal Policy-Making & Potential Impact on Biomedical Advances